Georgetown University, Lombardi Comprehensive Cancer Center is a clinical research site located in Washington D.C., District of Columbia, United States 20037.
Crixeo Health Trust Score: 68/100 (FAIR). This profile has not yet been claimed by the site owner.
Georgetown University, Lombardi Comprehensive Cancer Center has participated in 4 clinical trials with 1 currently active.
Therapeutic areas: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma, HER2-positive Breast Cancer.
Sponsors: Ono Pharmaceutical Co. Ltd, Pieris Pharmaceuticals, Inc., Karyopharm Therapeutics Inc.
Trust Score: 68/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Georgetown University, Lombardi Comprehensive Cancer Center has a Crixeo Trust Score of 68/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Georgetown University, Lombardi Comprehensive Cancer Center has 4 clinical trials on record, with 1 currently active. Their work covers Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma, HER2-positive Breast Cancer.
Georgetown University, Lombardi Comprehensive Cancer Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.